Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis

doi:10.19982/j.issn.1000-6621.20240567

Abstract

Abstract:

Objective: To explore the global research status and trends in basic research on Traditional Chinese Medicine (TCM) for prevention and treatment of tuberculosis (TB). Methods: We conducted a comprehensive literature review of Chinese and English publications related to basic TCM research against TB using Chinese national knowledge infrastructure, Wanfang database, PubMed and Web of Science database with a cutoff date of June 30, 2024. Bibliometric analysis was performed using CiteSpace and VOSviewer software to visualize publication metrics, author and institution networks, keywords clusters and the frequency of TCM interventions in both Chinese and English literature. Results: A total of 140 articles were included, contributed by 546 authors from 190 institutions, including 102 Chinese articles (72.86%) and 38 English articles (27.14%). The first publication appeared in 1961, with a noticeable increase in research output observed since 1993. In terms of journal distribution, the journal with the most Chinese publications was Chinese Journal of Antituberculosis (6.86%, 7/102), and the journal with the most English publications was Journal of Ethnopharmacology (10.53%, 4/38). Regarding author collaboration networks, the Chinese literature formed two research terms centered around “Wang Lixin and Wang Yi”, “Pan Jianhua, Shi Guomin, Xiang Yangen, Yu Rong”, respectively, while the English literature formed research teams centered around “Jiang Xin, Sun Jinxia, Zheng Yuejuan”. The institution collaboration network centered around “Shanghai University of Traditional Chinese Medicine” and “Changzhi Medical College.” Keyword clustering analysis in both Chinese and English literature revealed 16 distinct clusters, with research hotspots primarily concentrating on antibacterial effects and immunomodulation. Additionally, Prunella vulgaris, Radix Ranunculi Ternati, Radix stemonae, Rhubarb, Garlic were the most concerned single herb; baicalin, Radix Ranuncoli Ternati extracts, Allicin and Curcumin were the most TCM ingredients or extracts; while the combination of Bletilla striata (Thunb. ex A. Murray) Rchb. f. and Stemona japonica (Blume) Miq. (Bai Ji-Bai Bu) as the most strongly correlated herbal pair in TCM formulations. Conclusion: Basic research on TCM against TB has gained significant traction globally in recent years. The antibacterial effects and immune regulation mechanisms of TCM may become the future focus of development. Future investigations should enhance cross-sector and interdisciplinary collaborations to further elucidate the mechanisms underpinnings and optimize therapeutic patterns of TCM in TB prevention and treatment.

Key words: Tuberculosis, Medicine, Chinese Traditional, Basic research, Bibliometrics

CLC Number:

R52
R285.5

Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis[J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. doi: 10.19982/j.issn.1000-6621.20240567

Figures/Tables 14

References 47

[1]	胡鑫洋, 高静韬. 世界卫生组织《2024年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(6): 500-504. doi:10.19983/j.issn.2096-8493.2024164.
[2]	李杨, 孙峰, 张文宏. 结核病短程治疗研究: 回顾与展望. 中国防痨杂志, 2024, 46(9): 991-997. doi:10.19982/j.issn.1000-6621.20240219.
[3]	梁晨, 唐神结, 林明贵. 结核病综合治疗研究进展. 结核与肺部疾病杂志, 2024, 5(1): 70-80. doi:10.19983/j.issn.2096-8493.20230112.
[4]	Ge Q, Ma Y, Zhang L, et al. Effect of a modified regimen on drug-sensitive retreated pulmonary tuberculosis: A multicenter study in China. Front Public Health, 2023, 11: 1039399. doi:10.3389/fpubh.2023.1039399.
[5]	戈启萍, 张立杰, 黄学锐, 等. 首次复治敏感肺结核治疗新方案疗效的验证性研究. 中国防痨杂志, 2023, 45(11): 1078-1083. doi:10.19982/j.issn.1000-6621.20230192.
[6]	马艳, 高微微. 今非昔比:重视复治肺结核的合理施治. 中国防痨杂志, 2021, 43(4): 313-317. doi:10.3969/j.issn.1000-6621.2021.04.003.
[7]	孙慧娟, 苏伟, 陈伟. 利福平耐药结核病患者不良治疗结局及其影响因素研究进展. 结核与肺部疾病杂志, 2024, 5(6): 573-582. doi:10.19983/j.issn.2096-8493.2024111.
[8]	仵倩红, 张燕, 刘鑫. 多学科持续发力终结结核病流行. 结核与肺部疾病杂志, 2024, 5(4): 279-282. doi:10.19983/j.issn.2096-8493.2024052.
[9]	肖文静, 沈鑫. 进一步推进结核分枝杆菌潜伏感染管理加快实现终结结核病目标. 结核与肺部疾病杂志, 2024, 5(5): 385-387. doi:10.19983/j.issn.2096-8493.2024138.
[10]	陈伟, 孙慧娟, 赵雁林. 新时期我国结核病防治服务体系建设及展望. 结核与肺部疾病杂志, 2024, 5(2): 95-100. doi:10.19983/j.issn.2096-8493.2024025.
[11]	Rangaka MX, Frick M, Churchyard G, et al. Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment. Lancet Respir Med, 2023, 11(4): 380-390. doi:10.1016/S2213-2600(23)00084-X. pmid: 36966794
[12]	佟琳, 马艳, 范逸品, 等. 基于文献的清肺排毒汤组方治疫应用规律探讨. 中医杂志, 2021, 62(21): 1877-1881. doi:10.13288/j.11-2166/r.2021.21.007.
[13]	范逸品, 王燕平, 马艳, 等. 从新型冠状病毒肺炎的寒疫病机探析清肺排毒汤的组方机制. 中国实验方剂学杂志, 2020, 26(16): 1-5. doi:10.13422/j.cnki.syfjx.20201157.
[14]	Ji XY, Ma Y, Shi S, et al. Medication Rule Analysis of the Diagnosis and Treatment Programs of Chinese Medicine for the Prevention and Treatment of COVID-19 in China. Chin J Integr Med, 2022, 28(9): 779-784. doi:10.1007/s11655-021-2880-1.
[15]	Zhang H, Liu Y, Shang X, et al. Status and hotspot analysis of Qingfei Paidu Decoction for the prevention and treatment of COVID-19 based on bibliometric analysis. Front Pharmacol, 2024, 15: 1422773. doi:10.3389/fphar.2024.1422773.
[16]	Zhang L, Ma Y, Shi N, et al. Effect of Qingfei Paidu decoction combined with Western medicine treatments for COVID-19: A systematic review and meta-analysis. Phytomedicine, 2022, 102: 154166. doi:10.1016/j.phymed.2022.154166.
[17]	Xiong Y, Bao L, Ma Y, et al. Wen-Yi and Chinese medicine: Why we need to pay attention?. Sci Bull (Beijing), 2024, 69(11): 1617-1622. doi:10.1016/j.scib.2024.03.059.
[18]	Shang X, Cao Y, Guo Y, et al. Recent advancements in traditional Chinese medicine for COVID-19 with comorbidities across various systems: a scoping review. Infect Dis Poverty, 2024, 13(1): 97. doi:10.1186/s40249-024-01263-8.
[19]	Wang N, Yang MB, Yang PY, et al. A Case Series of Olfactory Dysfunction in Imported COVID-19 Patients: A 12-Month Follow-Up Study. Biomed Environ Sci, 2022, 35(5): 402-411. doi:10.3967/bes2022.056. pmid: 35676811
[20]	曹玉清, 尚希钰, 熊一白, 等. 青蒿素研发的成功经验对结核病防治的借鉴与启示. 结核与肺部疾病杂志, 2023, 4(6): 442-448. doi:10.19983/j.issn.2096-8493.20230089.
[21]	成诗明, 周林. 抗结核药品固定剂量复合剂应用手册. 北京: 北京大学医学出版社, 2023.
[22]	孙巧思, 胡镜清, 刘理想. 论中医学疫病防治特色. 中国中医基础医学杂志, 2021, 27(1): 42-45, 49.
[23]	徐信义, 邱仕君. 《十药神书》临床用药特色. 河南中医, 2006, 26(6): 21-23. doi:10.3969/j.issn.1003-5028.2006.06.014.
[24]	曹振东, 李磊. 补中益气汤辅助治疗肺结核患者的效果及不良反应评价. 中国防痨杂志, 2024, 46(S1): 70-72. doi:10.3969/j.issn.1000-6621.2024.z1.018.
[25]	李银虹, 刘芳琳, 鹿振辉, 等. 冬凌草甲素抗结核病理损伤的作用机制研究. 中国防痨杂志, 2022, 44(8): 849-854. doi:10.19982/j.issn.1000-6621.20220060.
[26]	刘明慧, 孙连杰, 李改改, 等. 观察补肺汤合生脉散加减治疗慢性阻塞性肺疾病稳定期肺气虚证患者肺功能和生活质量的影响. 中国防痨杂志, 2024, 46(z1): 120-122. doi:10.3969/j.issn.1000-6621.2024.z1.034.
[27]	邱磊, 张少言, 郭晓燕, 等. 化疗方案加芩部丹片治疗复治涂阳肺结核患者的临床价值. 中国防痨杂志, 2020, 42(2): 108-114. doi:10.3969/j.issn.1000-6621.2020.02.006.
[28]	费婉婉, 鹿振辉, 黄星, 等. 基于“肺与大肠相表里”探讨肠道菌群与肺结核关系的研究进展. 中国防痨杂志, 2022, 44(5): 500-504. doi:10.19982/j.issn.1000-6621.20210582.
[29]	庄丽, 马子风, 蒋雨薇, 等. 基于网络药理学的中药组方“芩部丹”治疗肺结核作用机制研究. 中国防痨杂志, 2022, 44(3): 273-283. doi:10.19982/j.issn.1000-6621.20210572.
[30]	鹿振辉, 张惠勇, 张洪春, 等. 我国中医药防治结核病的现状与展望. 中国防痨杂志, 2020, 42(2): 88-90. doi:10.3969/j.issn.1000-6621.2020.02.002.
[31]	夏露, 卢水华, 刘平. 中药对结核病免疫调控机制的研究进展. 中国防痨杂志, 2020, 42(2): 168-172. doi:10.3969/j.issn.1000-6621.2020.02.016.
[32]	马改霞, 田黎明, 王钰, 等. 中西医结合治疗耐多药肺结核的系统评价/Meta分析的再评价. 中国防痨杂志, 2020, 42(2): 95-100. doi:10.3969/j.issn.1000-6621.2020.02.004.
[33]	Wang M, Guan X, Chi Y, et al. Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials. Tuberculosis (Edinb), 2015, 95(4): 364-372. doi:10.1016/j.tube.2015.03.003.
[34]	彭草云, 阮月芳, 钱惠江. 初治肺结核患者体质与T淋巴细胞亚群关系的研究. 中国现代医生, 2023, 61(21): 1-4, 14. doi:10.3969/j.issn.1673-9701.2023.21.001.
[35]	韩章琴, 崔栋. 月华丸加减汤剂联合HRZE药物对肺结核患者痰菌转阴率及血清T淋巴细胞亚群水平的影响. 医学理论与实践, 2024, 37(7): 1132-1134. doi:10.19381/j.issn.1001-7585.2024.07.016.
[36]	张瑞霞, 陈瑞锋, 邓巧娟. 参麦注射液联合HRZE方案治疗肺结核的效果及对XOD、MMP-9水平的影响. 中华中医药学刊, 2021, 39(5): 70-73. doi:10.13193/j.issn.1673-7717.2021.05.019.
[37]	罗兰, 何国庆. 内消瘰疬丸联合2HRZE/4HR方案治疗肺结核的效果观察及对细胞因子和免疫功能的影响. 空军医学杂志, 2020, 36(1): 41-44. doi:10.3969/j.issn.2095-3402.2020.01.013.
[38]	Roldan-Valadez E, Salazar-Ruiz SY, Ibarra-Contreras R, et al. Current concepts on bibliometrics: a brief review about impact factor, Eigenfactor score, CiteScore, SCImago Journal Rank, Source-Normalised Impact per Paper, H-index, and alternative metrics. Ir J Med Sci, 2019, 188(3): 939-951. doi:10.1007/s11845-018-1936-5.
[39]	Huang C, Su J, Xie X, et al. A bibliometric study of China’s science and technology policies:1949—2010. Scientometrics, 2015, 102(2): 1521-1539. doi:10.1007/s11192-014-1406-4.
[40]	汪仲元. 大蒜、黄连索对结核菌抑制能方的测定. 山东医刊, 1961(11): 36.
[41]	Abbruzzese MR, Delaha EC, Garagusi VF. Absence of antimycobacterial synergism between garlic extract and antituberculosis drugs. Diagn Microbiol Infect Dis, 1987, 8(2): 79-85. doi:10.1016/0732-8893(87)90153-2.
[42]	黄烈雨, 王溪, 陈浩, 等. 基于网络爬虫的英国政府网站结核病主题政策发文计量分析. 中国防痨杂志, 2021, 43(11): 1199-1209. doi:10.3969/j.issn.1000-6621.2021.11.016.
[43]	Zhu Y, Han Q, Wang L, et al. Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway. J Ethnopharmacol, 2023, 301: 115763. doi:10.1016/j.jep.2022.115763.
[44]	刘媛, 陈洁, 孙辉, 等. 中药治疗肺结核的用药规律及其核心药物作用机制的探讨. 中国防痨杂志, 2022, 44(2): 131-140. doi:10.19982/j.issn.1000-6621.20210433.
[45]	束沛, 郑忻, 席瑞, 等. 百部治疗结核病的网络药理学分子机制研究. 辽宁中医药大学学报, 2021, 23(3): 107-113. doi:10.13194/j.issn.1673-842x.2021.03.024.
[46]	徐林霞, 明亮. 中草药抗结核分枝杆菌的实验研究. 长治医学院学报, 2007(3): 169-171. doi:10.3969/j.issn.1006-0588.2007.03.003.
[47]	Zhang C, Ning D, Pan J, et al. Anti-Inflammatory Effect Fraction of Bletilla striata and Its Protective Effect on LPS-Induced Acute Lung Injury. Mediators Inflamm, 2021, 2021: 6684120. doi:10.1155/2021/6684120.

期刊	发文量(篇)	被引频次	平均被引频次	影响因子
中文期刊
中国防痨杂志	7	56	8.00	2.253
时珍国医国药	4	109	27.25	1.938
长治医学院学报	4	53	13.25	0.440
中国药理学通报	3	82	27.33	2.426
中国中药杂志	3	199	66.33	5.185
英文期刊
Journal of Ethnopharmacology	4	140	35.00	4.800
Alternative Therapies in Health and Medicine	2	4	2.00	1.900
Bmc Complementary and Alternative Medicine	2	63	31.50	4.780
Molecular Medicine Reports	2	26	13.00	3.400
Phytotherapy Research	2	127	63.50	6.100
PLoS One	2	20	10.00	2.900

排序	国家	发文量(篇)	构成比(%)
1	中国	126	90.00
2	印度	5	3.58
3	美国	4	2.86
4	英国	2	1.43
5	韩国	1	0.71
6	加拿大	1	0.71
7	南非	1	0.71
合计	-	140	100.00

排序	省份	发文量(篇)	构成比(%)
1	北京市	22	17.46
2	上海市	15	11.90
3	浙江省	8	6.35
4	山东省	7	5.57
5	安徽省	6	4.76
6	山西省	6	4.76
7	湖北省	5	3.97
8	广东省	4	3.17
9	河南省	4	3.17
10	湖南省	4	3.17
11	四川省	4	3.17
12	云南省	4	3.17
13	重庆市	4	3.17
14	广西壮族自治区	3	2.38
15	贵州省	3	2.38
16	吉林省	3	2.38
17	海南省	2	1.59
18	黑龙江省	2	1.59
19	江苏省	2	1.59
20	江西省	2	1.59
21	甘肃省	2	1.59
22	辽宁省	2	1.59
23	青海省	2	1.59
24	陕西省	2	1.59
25	台湾省	2	1.59
26	天津市	2	1.59
27	新疆维吾尔自治区	2	1.59
28	河北省	1	0.79
29	香港特别行政区	1	0.79
合计	-	126	100.00

基金项目	小计(项)	构成比(%)	中文文献(篇)	构成比(%)	英文文献(篇)	构成比(%)
国家级	41	29.29	24	23.53	17	44.74
省部级	47	33.57	40	39.22	7	18.42
其他	14	10.00	6	5.88	8	21.05
无	38	27.14	32	31.37	6	15.79
合计	140	100.00	102	100.00	38	100.00

聚类名称	关键词(潜在语义索引)
#0结核分枝杆菌	结核分枝杆菌(13.38);抑菌作用(10.05);提取物(8.94);黄酮类化合物(8.92);益母草(8.92)
#1中草药	中医药(11.53);中医药疗法(8.92);肺结核(7.43);生脉散(4.46);一氧化氮(4.46)
#2细胞因子	细胞因子(13.38);耐多药结核分枝杆菌(13.38);免疫功能(11.53);猫爪草(10.38);功能(8.94)
#3异烟肼	异烟肼(13.38);肝损伤(8.94);黄芩苷(8.92);利福平(8.92);多巴胺神经元(4.46)
#4结核病	结核病(8.92);休眠菌(8.92);颗粒裂解肽(8.82);炎症介导素类(4.46);qc-rt-pcr(4.46)
#5抗结核药物	抗结核药物(8.92);NF-κB(8.92);肝损伤(6.92);抗结核(5.75);炎症介导素类(4.46)
#6双氢基青蒿	双氢青蒿素(8.92);青蒿素(6.92);抑菌率(4.46);抗结核活性(4.46);纳米药物(4.46)
#7抗结核	抗结核(5.75);分离和鉴定(4.46);三氯化铁(4.46);三氯化铝(4.46);白色针晶(4.46)
#8生脉散	生脉散(4.46);一氧化氮(4.46);抗痨(4.46);作用机制(4.46);治疗应用(4.46)